Immune cell chemical labeling chromogenic kit for auxiliary diagnosis of cervical cancer

Abstract

The invention relates to the technical field of cell chromogenic reagents, in particular to an immune cell chemical labeling chromogenic kit for auxiliary diagnosis of cervical cancer. The kit comprises a ready-to-use antibody working solution, a reagent solution C, a reagent solution D, a reagent solution E, a reagent solution F and a reagent solution G; the ready-to-use antibody working solution comprises an antibody reagent, bovine serum albumin, non-reducing sugar, fish skin gelatin, a preservative proclin-950, tender leaf green pigment, polyethylene glycol, casein, a surfactant, 4-aminoantipyrine and sodium chloride, and the antibody reagent comprises a reagent solution A and a reagent solution B. The kit can be used for cervical decellularization and can also be used for tissue staining. The blue returning mode is newly created, the blue returning effect is better than that of kits of other manufacturers in the market, the sheet sealing mode is simpler, and the experiment time is greatly shortened.

Description

technical field [0001] The invention relates to the technical field of cell chromogenic reagents, in particular to an immunocytochemical marker chromogenic reagent kit for auxiliary diagnosis of cervical cancer. Background technique [0002] At present, there is a patent document CN201510085334.8 which proposes to judge whether cervical epithelial tumor-like lesions occur by immunohistochemical double staining on cervical epithelial tissue specimens. This method is to judge whether high-grade neoplasia occurs by using immunoenzyme substrate chromogenic method for two markers phosphoprotein (stathmin) and mini-chromosome maintenance proteins (MCM2) in cervical squamous epithelial tissue samples. Lesions (CIN III). However, in this method, the sample is taken from cervical biopsy, which is an invasive test. On the one hand, it brings trauma to the individual. On the other hand, the current cervical cancer screening standard requires a second sampling of the patient, which inc...

AI Technical Summary

Problems solved by technology

However, in this method, the sample is taken from cervical biopsy, which is an invasive test. On the one hand, it brings trauma to the individual. On the other hand, the current cervical cancer screening standard requires a second sampling of the patient, which increases the difficulty of sampling; there is also this method. The diagnostic research of the two markers in precancerous lesions is still relatively limited, and the clinical application is even more limited

Images